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Dilated cardiomyopathy (DCM) is one the most common forms of heart failure, 
with the majority of cases being idiopathic.  Dr. Bennett’s laboratory previously 
showed that deletion of the Mgat1 gene in cardiomyocytes only (Mgat1KO) is 
sufficient to cause DCM leading to heart failure and early death. The Mgat1 gene 
product, GlcNAcT1, is responsible for initiating the formation of hybrid/complex 
N-glycosylation.  These data suggest a link between abnormal glycosylation and 
heart disease; however, there is a mystery of how the specific changes in 
glycosylation contribute to heart disease etiology and progression.  The proper 
function and gating of voltage-gated Na+ channels (Nav) and voltage-gated 
K+ channels (Kv) are vital to the initiation, shape, and conduction of the 
cardiomyocyte action potential (AP); thus, abnormal channel activity contributes 
to arrhythmias and other heart diseases.  Other labs as well as our own, have 
shown that modest reductions in channel glycosylation can alter gating of Nav 
and Kv through electrostatic mechanisms with no change in channel expression 
levels.  Thus, here and in a recent publication by Ednie, Parrish, Sonner, and 
Bennett entitled, “Reduced Hybrid/Complex N-glycosylation Disrupts Cardiac 
Electrical Signaling and Calcium Handling in a Model of Dilated 
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Cardiomyopathy“, we showed that cardiomyocyte-specific deletion of Mgat1 that 
leads to reduced hybrid/complex protein N-glycosylation modulates Nav and Kv 
activity through direct and indirect mechanisms.  Here, we show that Mgat1KO 
Nav expression was not different between Mgat1KO and control ventricular 
myocytes; however, there was a reduction in Mgat1KO Nav molecular weight, 
suggesting that Nav are direct targets of GlcNAcT1 similar to Cav a2d1.  We found 
that Kv4.2 and Kv1.5 expression levels are significantly lower in the older 
Mgat1KO ventricular myocyte compared to controls, consistent with an indirect, 
but disease-related decrease in Kv expression and, as a result, K+ current.  Thus, 
utilization of the Mgat1KO DCM model will allow one to continue uncovering 
mechanistic glycosylation-dependent links between aberrant electrical signaling 
and heart disease onset and progression.  
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A. Electrical Signaling, Conduction, and Contraction 
 
The human heart is a critical organ that provides for human life as well as 
maintains homeostasis by transporting nutrients, oxygen, and hormones.  
Without the pumping heart, life would end in a few short minutes.  The heart is 
part of the cardiovascular system that works synergistically with blood as well as 
blood vessels.  It is composed of four major chambers: the right atrium and right 
ventricle, and left atrium and left ventricle that carry deoxygenated and 
oxygenated blood respectively.  Coronary arteries supply the heart with nutrients 
that are located on the visceral pericardium.  The heart is composed of four 
layers: pericardium, epicardium, myocardium and endocardium.  Specifically, at 
the anatomical layer, the heart wall is composed of just three layers: epicardium, 
which is the outermost protective layer to the heart, myocardium, which is the 
muscular layer that contains the cardiomyocytes (cardiac tissue is solely located 
within the myocardial layer of the heart), and endocardium, which is the inner 
most layer is composed of simple squamous epithelium. This cardiac tissue is 
understood as involuntary, meaning mammals are not able to control the 
mechanical action that the heart provides.  The anatomical pacemaker (sinoatrial 
node) can be located in the right atrium, near where the superior vena cava 
opens.  The sinoatrial node (SA node) initiates the electrical signaling in the form 
of action potentials (AP), which conduct through the conduction system and then   
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results in exciting the myocardium. The myocardium subsequently contracts 
which allows the heart to pump blood.  The SA node sets up the heart rate, 
which, in humans, normally ranges from 60 – 100 beats per minute and is the 
source of sinus rhythms – allowing for the atria to fully contract before the 
ventricles. 
 The cells located in the SA node have self-sustaining and rhythmic 
changes in membrane potential.  Specifically, they are found to have a slow 
spontaneous 
depolarization 
during the period of 
diastole (1,2).  This 
is due to the fact 




myocytes that are 
responsible for the 
contraction of the 
heart.  The resting membrane potential for the SA node is approximately -60 mV 
and slowly depolarizes to approximately -40 mV, where threshold is achieved 
producing AP. However, the cardiomyocytes within the myocardium have a 
resting membrane potential roughly -90 to -80 mV (2,3).  The AP waveform of SA 
Figure 1: Electrical physiology of the myocardium in a human heart, 
with illustrated action potentials in the different conduction cells. 
Figure was taken (with permission) from Nerbonne and Kass (30). 
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nodal cells versus cardiomyocytes are quite distinct as shown in figure 1.  
Beginning with the SA nodal cells, the “funny current” (If) is conducted by a 
hyperpolarization-activated Na+ current, the voltage allowing for a gradual 
depolarization to threshold.  Once the nodal cells reach threshold, voltage-gated 
Ca2+ channels (Cav) open causing rapid depolarization.  From here voltage-gated 
K+ channels (Kv) repolarize the cell, returning it to its resting membrane potential.  
The AP’s generated from the SA node conduct along anterointernal pathways 
throughout atrial myocardium, via gap junctions that are located in the 
intercalated disc of the atrial myocyte, and finally collecting in the atrioventricular 
node (AV node).  The intercalated discs also contain desmosomes, which allow 
for cell-to-cell adhesion of adjacent cardiomyocytes.  The AV node depolarizes in 
a likewise fashion as the SA node (only if the SA node is not working), with 
gradual depolarization through the If current generating an AP as previously 
stated.  All cells capable of generating an AP will depolarize and repolarize in a 
similar manner.  Atrial and ventricular cardiomyocytes receive the AP from the 
conducting pathways.  Due to the ventricles being separated from the atria by the 
fibrous skeleton, modified cardiocytes are needed; atrioventricular node (AV 
node), atrioventricular bundle (Bundle of His) and Purkinje fibers. 
The cardiomyocytes begin to depolarize by AP’s from system conduction and 
other heart muscle cells, until threshold is met at approximately -70 mV with 
activated voltage-gated Na+ channels (Nav) initiating rapid depolarization (Phase 
0).  During phase 0, the myocytes will rapidly depolarize toward the Nernst 
potential for Na+, about +60 mV, but will never fully reach it (1,4).  These 
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activated Nav will undergo a second transition to an inactivated state and will not 
have the ability to reopen until transitioning back to a closed state.  This is known 
as the absolute refractory period (ARP), as a subsequent AP cannot fire during 
this time because there are insufficient Nav in the closed state and available to 
re-open (1).  Phase 1 is initiated by the inactivation of the Nav and the opening of 
the transient Kv4.2/4.3.  During phase 2, Ca2+ rapidly enters the cardiomyocyte 
from the extracellular fluid via L-type voltage-gated Ca2+ channels (Cav); the 
subsequent influx of Ca2+ will lead to activation of ryanodine receptors (RyR) 
located on the sarcoplasmic reticulum (SR) (1,4,5), through the process known 
as calcium induced – calcium release which plays a vital role in excitation-
contraction coupling in cardiac muscle (5).  Calcium ions from the SR are then 
released through activated RyR and bind to troponin, initiating the rippling 
cascade of myocardial contraction (1,4,5).  As phase 3 commences, the L-type 
Cav begin to inactivate, and the delayed rectifier Kv (1.5) are activating and 
thereby continue to allow potassium to flow freely returning the membrane 
toward the Nernst potential for potassium (6-8).  Phase 4, the final phase, the 
membrane has returned to resting and is ready for another AP (6,7).  These five 
phases are understood as the normal electrical signaling of human heart muscle.  
Here, we studied mouse ventricular voltage-gated ion channels (VGIC); as seen 
in figure 2, Nav and Cav isoforms are very similar between human and mouse 
cardiomyocytes; Kv particularly delayed rectifier Kv are quite different, explaining, 
in part, the distinct AP waveforms of human versus mouse cardiomyocytes.  
 
 5 
This is, Nav 1.5 in humans and mice is responsible for the depolarization 
phase.  Cav1.2 is seen in both models.  Kv 4.2 is looked at as being a transient Kv 
and comparable to Kv 4.3 in the human model.  Finally, Kv 1.5 and 2.1 are the 
slower, delayed-rectifier, repolarizing channels in the mouse that allow the 
myocyte to return to resting membrane potential.  The most obvious difference in 




Figure 2. Action potentials with underlying ion channels in the myocardium of mouse and 
human ventricles. Image was taken (with permission) from Nerbonne (9). 
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B. Cardiac Dysfunction  
Cardiomyopathies are divided into subtypes based on both morphological 
and functional phenotypes and are some of the most common precursors to HF, 
that lead to morbidity and mortality (24-27).  Dilated cardiomyopathy (DCM) can 
be characterized 




and dilation of 
chambers – both 
common after 
new onset of 
DCM (25,26,28-
30).  On average, there are 600,000 new diagnoses of heart failure per year in 
the United States with life expectancy after diagnosis approximately 5 years 
(24,28).  DCM takes the lives of 650,000 people annually, with the majority 
having an idiopathic etiology (24-26,28,31).  DCM plays a significant role in 
sudden cardiac deaths; further, DCM patients are the most likely to receive heart 
transplants in children and adults worldwide (25,26). 
Heart failure (HF) is described as failure of the heart to pump blood 
efficiently through the body, secondary to electrical and contractile dysfunction 
(10).  Patient’s will not only have circulatory issues, but they are more likely to 
Figure 3: Known cardiomyopathies classification; ARVC, 
arrhythmogenic right ventricular cardiomyopathy; DCM, dilated 
cardiomyopathy; HCM, hypertrophic cardiomyopathy; RCM, restrictive 
cardiomyopathy. Figure was adapted (with permission) from Elliot et. al 
(8). 
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develop arrhythmias (10,11).  Heart failure has shown alterations in VGIC, gap 
junctions, and structural changes (10).  As described above, several VGIC 
contribute to the normal generation of an AP and some channels are dependent 
on each other and are responsible for the calcium induced – calcium release 
mechanisms.  Studies have shown a correlation between electrical and 
mechanical dysfunction through channelopathies (10).  Nav and KV mutations can 
demonstrate a deficit in channel surface expression that may be linked to cardiac 
diseases after removing the entire N-glycan (6,12).  In our work, we have found 
the modest changes in N- glycosylation that represents a more 
pathophysiological scenario (we cannot live without N-glycosylation), in fact does 
not change surface expression.  This is unique, as other groups have removed 
the entire N-glycan, which could potentially impact surface expression.  
 Cardiac dysfunction can affect the right or left ventricle; however, 
congestive heart failure typically involves significant dysfunction of the left 
ventricle (13).  Though there is no cure for congestive heart failure, it can be 
treated (14,15).  Before science had evolved and treatment options became 
available, patients with viral myocarditis, alcohol cardiomyopathy, and post-
partum cardiomyopathy were the only ones who stood a chance to regain left 
ventricular function (14).  Today patients have the ability to be treated with b-
blockers (15-17), angiotensin receptor blockers (15,18), aldosterone receptor 
blockers (15,19-21), angiotensin-converting enzyme (ACE) inhibitors (15,22), as 
well as cardiac resychronisation therapy (15,23).  
 
 8 
C. Glycosylation and Cardiac Function 
Normal cardiac function is needed to maintain a healthy life.  In order to 
maintain normal cardiac function, past studies have shown that 
glycosyltransferases and glycosidases are required for normal homeostatic 
physiology (33).  Several glycan types can be linked to proteins, but the most 
abundant are the oligosaccharides (N-linked glycans) (34-36).  Oligosaccharides 
can be added en bloc to the Asparagine residue that initiates the consensus N- 
glycosylation site of Asparagine-X-Serine/Theronine. Sugar residues are then 
added to and removed from the N-glycan structure co-translationally in the lumen 
of the rough endoplasmic reticulum (RER), and then possibly follow a designated 
default pathway to several locations such as the plasma membrane, 
peroxisomes, extracellular space, or other organelles (34).  Initially, the 
oligosaccharides are attached to dolichol (lipid) and then transferred to 
asparagine (N) during translocation.  N-glycans will reach the Golgi complex, 
which is a common place for post-translational modification and packaging.  Also, 
the high-mannose glycans will become complexed/hybrid glycoproteins as they 
make their way through the Golgi (37).  This formation of oligosaccharides is a 
critical cellular process that is necessary for sustainable cardiac function and 
requires the activity of many glycogenes (32,38).  The hybrid/complex N-glycans 
are often directed to the sarcolemma with multiple proteins that range in function 
from ion channels, receptors, and cell adhesion molecules (30,38).  The 
oligosaccharide chains are sensitive to enzymes that function to cleave complete 
carbohydrate chains or single monosaccharides (34).  Previous studies from the 
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Bennett lab and others have shown glycogene expression that results in 
abnormal glycosylation in cardiomyocytes of both atria and ventricles correlate 
with arrhythmias, DCM and HF (24,32,38, 39-42).  Furthermore, models with 
DCM and HF have shown to be related to the abnormal glycosylation of voltage 
gated ion channels (VGIC), particularly Nav and Cav (43,44).  At the molecular 
and cellular level, it has yet to be identified if the changes in cardiomyocyte 
glycosylation is pathogenic or a consequence of DCM (38,44,45). 
 
D. Role of Hybrid and Complex N-glycosylation in cardiac function  
The glycosyltransferase, N-acetylglucosaminyltransferase 1 (GlcNAcT1), 
is the gene product of mannosyl (a-1,3-)-glycoprotein b-1,2-N-
acetylglucosaminyltransferase 
(Mgat1) is responsible and 
necessary for formation of the 
complex/hybrid N-glycans in 
the medial cisternae of the 
Golgi apparatus.  
Glycosylation occurs in the 
cis Golgi network (CGN) 
where the first N-acetylglucosamine (GlcNAc) residue is attached to a mannose 
residue of the N-glycan structure (46).  Proteins that reach GlcNAcT1 are 
correctly folded; therefore, an unfolded protein response is unlikely exacerbated 
by the deletion of Mgat1 (38,47,48).  Studies have shown there are rare 
Figure 4. Schematic of control vs Mgat1KO in mouse 
ventricular cardiomyocytes. Figure was taken (with 
permission) from Ednie et. Al (38).  
 10 
occasions that Mgat1 is reduced.  Focusing on Mgat1 after being identified as a 
critical gene in human idiopathic DCM (38,49), could show the role that 
complex/hybrid N-glycosylation plays in cardiac function and heart diseases. 
The Bennett lab has shown that modest changes in cardiac N-
glycosylation directly modulate VGIC gating through electrostatic mechanisms, 
but with no effect on channel surface expression; the sialylation-dependent 
changes in VGIC gating are sufficient to increase susceptibility to cardiac 
arrhythmias (50-53).  Terminal sialic acid residues are negatively charged at 
physiologic pH, and thereby contribute to the membrane potential sensed by the 
voltage sensors of the VGIC such that channels gate at less depolarized 
potentials in the presence of functional sialic acids.  As glycosylation (sialylation) 
is reduced, so is the negative external surface potential, and thereby VGIC gate 
only following greater depolarizations.  Recently, the Bennett lab showed that 
these same reductions in sialylation are sufficient to also cause stressed-induced 
heart failure suggesting a glycosylation-dependent link between excitability and 
contraction in the heart (54).  For this study we used our DCM mouse model 
(Mgat1KO), to show the impact in VGIC dysfunctions after the deletion of protein 
complexed/hybrid N-glycans. 
Recently, and prior to my arrival to the lab, the Bennett lab successfully 
established this unique mouse model with DCM secondary to pathologic 
deletions of hybrid/complex N-glycosylation by developing a model where an 
isolated glycosyltransferase gene, Mgat1, was knocked out in cardiomyocytes 
only (55).  Normal cardiac function is dependent on Mgat1 expression and has 
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been seen to be down regulated in humans with end stage idiopathic DCM 
(38,49, 55-58).  GlcNAcT1, the Mgat1 gene product, is responsible and 
necessary for the formation hybrid/complex N-glycans via the CGN, attaching the 
first GlcNAc residue to a mannose residue (59).  Therefore, GlcNAcT1 will only 
act on proteins that have made it beyond the protein folding checkpoint in the ER 
pathway (60).  The Bennett lab showed that hybrid/complex N-glycans are 
reduced in the cardiomyocyte membrane proteins of the Mgat1KO and develop 
DCM that leads to an early death (55).  Further, the Mgat1KO model confirmed 
effects on myocyte e-c coupling and contraction, consistent with a direct effect on 















II. Materials and Methods 
Experimental animals 
 Experimental protocols were approved by the Institutional Animal Use and 
Care Committee at Wright State University.  The animals were handled following 
the outline set by the NIH’s Guide for the Care and Use of Laboratory Animals.   
 
Creation of Mgat1KO model 
 Creation and initial characterization of the cardiomyocyte-specific 
Mgat1KO model was described in a recent publication from the Bennett lab (38), 
in which the breeding, genotyping and selection of wild type and experimental 
animals was described (38). 
 
Western Blot and Immunodetection 
 To obtain whole protein lysates, hearts were homogenized using 1.5 mL 
bead tubes that contained the following buffer (mM/L) Bis-Tris 20; pH7.2, EGTA 
10, NaF 50, NaCl 100, Na+ pyrophosphate 25, MgSO4 3. We also added 0.02% 
Na+ azide to act as a preservative, 1x Roche Complete Mini protease inhibitor 
tablet, and 10 µM Calpain inhibitors I and II (APExBio).  After the hearts were 
homogenized, the lysates were brought to 1% glyco-diosgenin (Anatrace) from a 
10% stock in lysis buffer.  Protein solubilization took place at 1 hour with gentle 
end-over-end mixing at 4° C and then centrifuged.  SDS-PAGE and western 
blotting conducting by using a Bis-Tris based buffer system as previously 
described (38,50,51).  Antibodies specifically for Kv2.1, Kv4.2 and Nav were used 
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as previously described (50,51,53).  Antibodies for Kv1.5 and MiRP1 were from 
Alamone and the antibody for anti-KChiP2 came from Neuromab.  The total 
protein staining was carried out by adding 2,2,2-trichloroethanol to the running 
gels as done in previous experiments (38) and all Western blots were analyzed 
using Image Lab, software from Bio-Rad.  
 
Data analysis and statistics 
 Excel (Microsoft) and Image Lab (Bio-Rad) software programs were used 
to analyze the raw data collected.  SigmaPlot (Systat Software) provided the 
capability of statistical analyses and graphs and figures were made with Prism 
(GraphPad).  For statistical analysis, Student’s t-test was used as appropriate. P 
values were calculated and were found to be statistically significant when p< 
0.05. Data on graphs are presented as the mean ± SEM.  Percent changes were 
figured in as the absolute value of differences between Mgat1KO and control, 










III. Results  
A manuscript by A.R. Ednie, A.R. Parrish, M.J. Sonner and E.S. Bennett 
entitled, “Reduced Hybrid/Complex N-glycosylation Disrupts Cardiac Electrical 
Signaling and Calcium Handling in a Model of Dilated Cardiomyopathy“, was 
recently accepted for publication and can be found at the following URL: 
https://doi.org/10.1016/j.yjmcc.2019.05.001.  In this report, the lab investigated 
whether there is a direct glycosylation-dependent functional linkage between 
cardiac and cardiomyocyte electrical and contractile functions using our 
Mgat1KO DCM mouse model.  We concluded that the Mgat1KO ventricular 
cardiomyocytes presented with a significant decrease in Kv expression leading to 
APs of greater duration.  The reduction in Ik (due to reduced Kv activity) 
worsened with disease (DCM) progression, likely due to indirect effects of Mgat1 
deletion.  Furthermore, the lab was successful in showing that Nav gating is 
depolarized in the Mgat1KO model, with Nav expression and conductance 
unaffected, supporting that there is a direct electrostatic effect of Mgat1 deletion 
on the Nav that contains fewer hybrid/complex N-glycans.  Hence, the report in 
FASEB J. by Ednie et al (38), together with the recent paper on which I am a co-
author (71), showed a drastic change in VGIC (Cav and Nav) gating that was 
directly related to Mgat1 deletion, and consistent with an electrostatic 
mechanism.  Further, indirect effects on Mgat1 deletion resulted in reduced K+ 
current and Kv expression that were secondary to direct effects on VGIC gating 
and worsened with disease progression. 
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My contribution to this work focused primarily on experiments designed to 
determine the relative expression levels of the three major cardiac Kv isoforms, 
and whether they were consistent with the observed significant, apparent 
disease-related decrease in Mgat1KO Kv currents (IK) that occur during the 
ventricular AP of the Mgat1KO.  Further, I investigated whether the Nav 
expression levels remained constant in control and Mgat1KO myocytes. 
The three major Kv isoforms that are collectively responsible for ventricle 
repolarization, Kv4.2 (Ito), Kv1.5 (IK,Slow1), and Kv2.1 (IK,Slow2), were targets of 
interest for the reasons described above.  Briefly, Dr. Andrew Ednie in the lab 
showed that IK is reduced in 8-20 week old Mgat1KO ventricular myocytes 
compared to control IK levels, but only modestly reduced in 4 week old ventricular 
myocytes; together these data suggest that the reduction in IK may, at least in 
part, be the result of ion channel remodeling that worsens with disease 
progression.  Thus, to determine whether Kv expression is reduced consistent 
with the disease-related reductions in IK observed, total protein lysates were 
collected from 16-20 week old Mgat1KO and control hearts, separated by SDS-
PAGE, Western blotted and finally probed with specific antibodies for the three Kv 
isoforms.  Kv1.5 and Kv4.2 expression levels were significantly lower in the 
Mgat1KO hearts, compared to the controls (Fig. 5A and 5B, composite data in 
Fig. 6).  However, surprisingly Kv 2.1 (Fig 5C, 6) expression was higher in the 
Mgat1KO hearts, which was not expected.  Thus, Martha Sonner in the lab 
questioned whether the reduction of Kv2.1 current could be due to reduced 
surface expression.  Specifically, Martha tagged surface proteins of 
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cardiomyocytes with an amine-reactive biotin molecule.  Using neutravidin 
coated beads, allowed for the beads to adhere to the biotinylated surface 
proteins.  Kv2.1 surface protein expression was not seen to be affected in the 
cardiomyocytes of the Mgat1KO (but was not increased in the Mgat1KO as 
suggested by the whole cell lysate experiments, see Figs. 5C and 6).  Analyzing 
other channels in the Mgat1KO, surface expression of Kv1.5, Kv4.2 and the K+ 
channel interacting protein 2 (KChiP2), which regulates Kv4.2 expression (61) 
were all significantly lower.  However, the Kv auxiliary protein MiRP1 (KCNE2) 

















Figure 5. Kv but not Nav expression is redued in the Mgat1KO ventricle; Nav is reduced in 
molecular weight of Mgat1KO compared to controls. Top Panels: Immunoblots of whole 
protein lysates that are probed with anti-VGIC antibodies. Bottom Panels: Gels corresponding 
to the blot in the top panel stained for total protein. A) Nav. Nav expression is similar in the 
ventricles of controls and Mgat1KO; however, there is a slight in molecular weight 
(approximately 5 kD) in the Mgat1KO (N=3). (B) Kv1.5. (C) Kv4.2. (D) Kv2.1.  The data suggest 
that there is a reduction in expression of Kv1.5 and Kv4.2 and an increase in Kv2.1 expression 
in the ventricles of Mgat1KO. Figure was adapted from Ednie, Parrish, Sonner, and Bennett, 
2019. 
 
Figure 6. Composite 
data showing the relative 
whole cell protein levels 
of the three Kv isoforms 
and Nav from Mgat1KO 
(red) versus control 
(black) lysates. Figure is 
adapted from Ednie, 











Figure 7. Work was completed by Martha Sonner, where surface proteins of cardiomyocytes 
were tagged with an amine-reactive biotin molecule.  The biotinylated proteins were collected, 
Western blotted and probed with the appropriate antibodies.  The surface protein/antibodies 
were normalized to total protein, as described in the Methods.  The bottom panel shows that 
there is a reduction in surface expression of Kv4.2, Kv1.5 and KChiP2, in the cardiomyocytes 
of Mgat1KO.  However, the surface expression for MiRP1 was higher in the Mgat1KO 
cardiomyocytes in comparison to the control (N=4; p≤0.04).  There was no statistical 
significant differences in the surface expression in Kv2.1 in Mgat1KO versus control, when 
comparing the two groups. Figure is taken from Ednie, Parrish, Sonner, and Bennett, 2019.  
 
 19 
Nav expression nor INa in Mgat1KO and control were different, but unlike 
Kv, Nav is apparently a direct GlcNAcT1 target.  There was no significant 
difference in the expression comparing Mgat1KO and control ventricles as 
indicated in the Nav Western blot (Figs. 5A, 6).  There was a slight reduction in 
predicted molecular weight of the Mgat1KO Nav (Fig. 5A), which suggests that 
Mgat1KO contains Nav channels that are less N-glycosylationed and are thus a 
likely direct GlcNAcT1 target.  To determine if Kv1.5 (Kv4.2 and Kv2.1 are not N-
glycosylated, and thus cannot be GlcNAcT1 targets) are also potential direct 
targets of GlcNAcT1, immunoblot gel shift analyses were performed using whole 
protein lysates from the Mgat1KO and control ventricles (Fig. 8).  
 
 
Endoglycosidase H (Endo-H) and Peptide: N-glycosidase F (PNGase F) are 
commonly used enzymes that will cleave off high mannose and full N-
glycoproteins respectively.  Previously, Dr. Ednie showed, using this pair of 
enzymes, that the Cava2d1 is a target for GlcNAcT (38), which we further 
confirmed here in Figs. 8 and 10.  Kv4.2 and Kv2.1 do not contain any putatively 
Figure 8. (A)  Mgat1KO Cava2d1 after being treated with Endo-H shows sensitivity meaning 
that it is a target for GlcNAcT1.  (B) and (C) are both probed with antibody specific for Kv1.5 
after being treated with Endo-H and PNGase-F respectively.  Both blots showed no sensitivity 
to either enzyme treatment in the control or in the Mgat1KO lysates, as there was not a 
noticeable shift in molecular weight, suggesting Kv1.5 is not a target for GlcNAcT1. 
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extracellular consensus N-glycosylation sites (NXS/T), and therefore neither Kv 
isoform can be GlcNAcT1 targets.  On the other hand, Kv1.5 does contain one 
potential external N-glycosylation site.  However, as can be seen in Figs. 8 and 
















Figure 9.  
Top panel.  Immunoblot, probed with an antibody specific for Kv1.5 showed no enzyme 
sensitivity.  Whole protein lysates of ventricular cardiomyocytes were treated with Endo-H and 
compared to untreated lysates. 
 
Bottom panel.  Immunoblot, probed with a second antibody for Kv1.5 from Santa Cruz, to 
confirm it is not a target for GlcNAcT1.  Whole protein lysates of ventricular cardiomyocytes 
were treated with Endo-H and compared to untreated lysates. 
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With that stated, the predicted increased electrophoretic mobility represented by 
a decreased molecular weight (MW) in the Mgat1KO Kv1.5 should it be a 
GlcNAcT1 target, would be quite small (hundreds of daltons), and thus, we will 
need to perform more sensitive assays such as HILIC analysis similar to that 
does by us previously (38) to determine more rigorously whether Kv1.5 is a direct 
GlcNAcT1 target.  Regardless, the further reduction with disease progression, in 
IK,slow1, which is produced by Kv1.5 activity, along with the disease-related 
reductions in Kv4.2 (Ito) and Kv2.1 (IK,slow2) activities, strongly suggests that there 
is at least some disease-related indirect effects of Mgat1 deletion on Kv activities, 








Figure 10. Immunoblot, probed with an antibody specific for Cava2d1 showed 
enzyme sensitivity, confirming that Cava2d1 is a target for GlcNAcT1.  Whole protein 




In our recent publication by Ednie, Parrish, Sonner, and Bennett (71), 
entitled, “Reduced Hybrid/Complex N-glycosylation Disrupts Cardiac Electrical 
Signaling and Calcium Handling in a Model of Dilated Cardiomyopathy“, we 
showed that Nav gating was directly altered by Mgat1 deletion through 
mechanisms consistent with an electrostatic mechanism.  Further, indirect effects 
of Mgat1 deletion resulted in reduced K+ current and Kv expression that were at 
least secondary to direct effects on Nav and Cav gating and worsened with disease 
progression.  Together, these direct and indirect effects of Mgat1 deletion resulted 
in extended cardiomyocyte APs, pacing-induced early re-activation events, and 
altered Ca2+ handling as well as aberrant conduction across the heart. 
Here we found that (Fig. 5A), when comparing to previous studies done in 
the lab, that Mgat1 deletion in cardiomyocytes suggest there is no further effect 
on the function of Nav other than a reduced negative surface potential caused by 
reductions in Nav sialic acids.  There was no change in Nav expression, but there 
was a reduction in channel molecular weight, suggesting that Nav, like Cava2d1, is 
a GlcNAcT1 target.  These effects support the observed changes in AP 
properties of Mgat1KO ventricular myocytes.  
Relative to Kv expression, we found that Kv4.2 and Kv1.5 are significantly 
reduced in the 16-20 week old Mgat1KO compared to the age-matched control.  
These data are consistent with the significantly reduced Ito and IK,Slow1 that 
worsens with age as shown by Andrew Ednie in our recent publication (71).  
Further, we showed that surface expression of these two Kv isoforms are 
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significantly lower in the Mgat1KO ventricular myocyte compared to controls (Fig. 
8). 
 The increased expression of Kv2.1 (Fig. 5C), and even the lack of the 
reduction in Kv2.1 surface expression was surprising; however, the data are 
consistent with a study analyzing the impact of repolarization in a transaortic 
constriction mouse model with cardiac hypertrophy (64).  McCrossan et. al, 
showed that MiRP1, an auxiliary subunit, can reduce expression of Kv2.1 activity 
and slow down inactivation, similar to that shown here in our recent publication 
(72).  We showed, in figure 7, that MiRP1 surface expression is significantly 
higher in the cardiomyocytes of Mgat1KO.  Thus, it is a possibility that the 
deletion of Mgat1 regulates the effects of Mgat1 deletion on Kv2.1, after an 
increase in surface expression of MiRP1.  More testing is required to solidify this 
possible mechanism.   
Kv1.5 has been seen to be a direct target of cardiac remodeling (64,65) 
and is downregulated in models with DCM (66).  Therefore, there are two main 
ideas: Kv1.5 is an early target of cardiac remodeling and/or a direct GlcNAcT1 
target.  Our results suggest that Kv1.5 is not a target of GlcNAcT1 (Fig 9).  In 
addition, other labs have shown that there were effects of reduced glycosylation 
on surface expression of the Kv isoforms, but in these studies by others, 
glycosylation was completely removed either through mutation of the N-
glycosylation site or using chemicals to remove or inhibit the complete N-glycan 
(12, 68).  This is servere and not commonly seen in pathological glycosylation 
reductions.  Our lab’s DCM mouse model prevents only hybrid/complex N-
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glycosylation and in cardiomyocytes only, thus not affecting the core N-glycan 
structure (Fig 4).  This model is more comparable to glycosylation-deficient 
diseases known as congenital disorders of glycosylation. As mentioned 
previously, GlcNAcT1 functions in the Golgi apparatus, specifically medial portion 
initiating hybrid/complex N-glycosylation.  Prior to this along the N-glycosylation 
pathway, there is the protein-folding checkpoint of the ER pathway, verifying that 
proteins are correctly folded (47). GlcNAcT1 acts after the ER protein checkpoint, 
likely ensuring the proper folding of proteins in the Mgat1KO myocyte.  Finally, 
Dr. Ednie, in our recent publication, showed that IK is further reduced as DCM 
progresses in the Mgat1KO (71).  Together, these data strongly suggest that 
reduced Kv expression and activity, including for Kv1.5, is an indirect effect of 
Mgat1 deletion that is exacerbated as heart disease progresses. 
 
Correlation of VGIC activity to heart disease 
Currently, there are numerous Nav mutations correlatedto cardiac arrhythmic 
DCM (62,63).  Studies comparing the progression of disease and the Nav 
dysfunction is obscure (63), but it is known that of the seventeen best understood 
DCM-related Nav mutants, five have mutations result in a rightward-shift in 
steady-state activation, inactivation or both, similar to that seen in our recent 
paper, for Mgat1KO Nav gating (62).  Thus, ongoing studies in the lab will 
question whether disease progression can be slowed in the Mgat1KO heart via 
targeting Nav activity.  These research studies may lead to the development of 
new therapeutic techniques in treating patients who present with congenital 
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disorders of glycosylation or patient’s with Nav mutations correlated to DCM.  
There is an extreme importance of Kv1.5, as it is understood to have a significant 
role in the linage to human atrial fibrillation (68).  As the studies pertaining to 
aberrant glycosylation continue, utilizing the Mgat1KO DCM model will be a very 
useful tool. 
As mentioned earlier, the direct, right-ward shift in Nav gating causes the 
slower inactivation of the channels, which then increases the influx of Na+ during 
the prolonged AP.  This dramatic influx of Na+ has been linked to the disruption 
of Ca2+ homeostasis and leading to arrhythmias (61,70).  The three Kv isoforms 
are very likely indirectly affected through prolonged cardiac disease.  
 
Future studies 
As our lab continues to study hybrid/complex N-glycans, other projects will aid 
in the bigger picture of our project and allow for a deeper understanding to DCM.  
It would be beneficial in determining the actual distribution of the effects of 
deletion of the enzyme, GlcNAcT1.  To determine this, one could use the 
biotinylated Galanthus Niavalis Lectin (GNL), a carbohydrate-binding protein that 
binds specifically to mannose-specific lectins (the dominant N-glycan structure in 
Mgat1KO myocytes).  However, unlike other mannose-specific lectins, GNL does 
not require Ca2+ or Mn2+.  The questions we ask pertaining to this are, will we 
even see the distribution? or Can we determine the percent of the 
cardiomyocytes that are complete or partial KO?  It is also of interest that we try 
to find the time window of when fibrotic tissue presents itself on the gross level 
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on mice with Mgat1KO.  Paraffin fixation with trichrome blue stain would be an 
option as well as cryofixation paired with using a cryostat.  Finally, measuring the 




The glycosylation of proteins is ubiquitous to molecular and cellular processes 
and can even be thought to have an evolutionary purpose.  Understanding the 
role of glycosylation gives scientist a greater knowledge of how this affects 
human health and relates to the cause of disease.  However, the research on 
aberrant N-glycosylation is elusive, and there are multiple questions on cardiac 
dysfunction that are not understood.  What is known is that the defects in 
glycosylation and glycogene expression leads to cardiac diseases such as DCM, 
which is typically accompanied by arrhythmias.  Unfortunately, the functional 
linkage between altered glycosylation and disease progression is not fully 
understood.  Our lab, through efforts made in this project and in previous studies, 
showed that reduced hybrid/complex N-glycosylation directly and indirectly 
modulates cardiomyocyte and cardiac electrical signaling.  Our recent paper (71) 
provides a possible explanation that links these direct and indirect mechanisms 
to the abnormal contractions leading to DCM in the Mgat1KO and the onset of 
cardiac disease (38).  Utilization of this mouse model will allow one to continue 
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